{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T19:07:17Z","timestamp":1761937637178,"version":"build-2065373602"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1994,5,1]],"date-time":"1994-05-01T00:00:00Z","timestamp":767750400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[1994,5]]},"DOI":"10.1007\/bf01830241","type":"journal-article","created":{"date-parts":[[2005,6,28]],"date-time":"2005-06-28T03:48:49Z","timestamp":1119930529000},"page":"227-233","source":"Crossref","is-referenced-by-count":43,"title":["Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA)"],"prefix":"10.1007","volume":"5","author":[{"given":"Lynda F.","family":"Voigt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01830241_CR1","volume-title":"Endometrial Cancer","author":"LF Voigt","year":"1989","unstructured":"Voigt LF, Weiss NS. Epidemiology of endometrial cancer, In: Surwit EA, Alberts DS, eds.Endometrial Cancer. Boston, MA, USA: Kluwer Academic Publishers, 1989."},{"key":"BF01830241_CR2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0140-6736(91)90417-N","volume":"338","author":"LF Voigt","year":"1991","unstructured":"Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer.Lancet 1991;338: 274\u20138.","journal-title":"Lancet"},{"key":"BF01830241_CR3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJM198010303031807","volume":"303","author":"DW Kaufman","year":"1980","unstructured":"Kaufman DW, Shapiro S, Slone D, et al. Decreased risk of endometrial cancer among oral-contraceptive users.N Engl J Med 1980;303: 1045\u20137.","journal-title":"N Engl J Med"},{"key":"BF01830241_CR4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM198003063021004","volume":"302","author":"NS Weiss","year":"1980","unstructured":"Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives.N Engl J Med 1980;302: 551\u20134.","journal-title":"N Engl J Med"},{"key":"BF01830241_CR5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jama.1982.03320290021022","volume":"247","author":"BS Hulka","year":"1982","unstructured":"Hulka BS, Chambless LE, Kaufman DG, Fowler WC, Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives.JAMA 1982;247: 475\u20137.","journal-title":"JAMA"},{"key":"BF01830241_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/oxfordjournals.aje.a113417","volume":"116","author":"JL Kelsey","year":"1982","unstructured":"Kelsey JL, LiVolsi VA, Holford TR, et al. A case-control study of cancer of the endometrium.Am J Epidemiol 1982;116: 333\u201342.","journal-title":"Am J Epidemiol"},{"key":"BF01830241_CR7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bjc.1983.127","volume":"47","author":"BE Henderson","year":"1983","unstructured":"Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women.Br J Cancer 1983;47: 749\u201356.","journal-title":"Br J Cancer"},{"key":"BF01830241_CR8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bjc.1986.178","volume":"54","author":"C Vecchia La","year":"1986","unstructured":"La Vecchia C, Decarli A, Fasoli M, et al. Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study.Br J Cancer 1986;54: 311\u20137.","journal-title":"Br J Cancer"},{"key":"BF01830241_CR9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jama.1987.03390060086029","volume":"257","author":"CASH","year":"1987","unstructured":"CASH. Combination oral contraceptive use and the risk of endometrial cancer.JAMA 1987;257: 796\u2013800.","journal-title":"JAMA"},{"key":"BF01830241_CR10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00053128","volume":"2","author":"F Levi","year":"1991","unstructured":"Levi F, La Vecchia C, Gulie C, et al. Oral contraceptives and the risk of endometrial cancer.Cancer Causes Control 1991;2: 99\u2013103.","journal-title":"Cancer Causes Control"},{"key":"BF01830241_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/00016348609155179","volume":"65","author":"B Pettersson","year":"1986","unstructured":"Pettersson B, Adami HO, Bergstrom R, Johansson EDB. Menstruation span\u2014a time-limited risk factor for endometrial carcinoma.Acta Obstet Gynecol Scand 1986;65: 247\u201355.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"BF01830241_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.2910540214","volume":"54","author":"JL Stanford","year":"1993","unstructured":"Stanford JL, Brinton LA, Berman ML, et al. Oral contraceptives and endometrial cancer: Do other risk factors modify the association?Int J Cancer 1993;54: 243\u20138.","journal-title":"Int J Cancer"},{"key":"BF01830241_CR13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ije\/17.2.263","volume":"17","author":"WHO Collaborative Study of Neoplasia and Steroid Contraceptives","year":"1988","unstructured":"WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Endometrial cancer and combined oral contraceptives.Int J Epidemiol 1988;17: 263\u20139.","journal-title":"Int J Epidemiol"},{"key":"BF01830241_CR14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0010-7824(85)90056-3","volume":"31","author":"LJ Dorflinger","year":"1985","unstructured":"Dorflinger LJ. Relative potency of progestins used in oral contraceptives.Contraception 1985;31: 557\u201370.","journal-title":"Contraception"},{"key":"BF01830241_CR15","first-page":"37","volume":"18","author":"RB Greenblatt","year":"1967","unstructured":"Greenblatt RB. Progestational agents in clinical practice.Med Sci 1967;18: 37\u201349.","journal-title":"Med Sci"},{"key":"BF01830241_CR16","first-page":"18","volume":"26","author":"GIM Swyer","year":"1982","unstructured":"Swyer GIM. Potency of progestogens in oral contraceptives-further delay of menses data.Contraception 1982;26: 18\u201322.","journal-title":"Contraception"},{"key":"BF01830241_CR17","volume-title":"International Encyclopedia of Pharmacology and Therapeutics","author":"J Ferin","year":"1972","unstructured":"Ferin J. Orally active progestational compounds. Human studies: effects on the utero-vaginal tract. In:International Encyclopedia of Pharmacology and Therapeutics. Oxford, UK: Pergamon, 1972, Chapter 30, Sect. 4, Vol. 2."},{"key":"BF01830241_CR18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1471-0528.1967.tb15578.x","volume":"74","author":"ECG Grant","year":"1967","unstructured":"Grant ECG. Hormone balance of oral contraceptives.J Obstet Gynaec Brit Cwlth 1967;74: 908\u201318.","journal-title":"J Obstet Gynaec Brit Cwlth"},{"key":"BF01830241_CR19","first-page":"106","volume":"47","author":"RP Dickey","year":"1976","unstructured":"Dickey RP, Stone SC. Progestational potency of oral contraceptives.Obstet Gynecol 1976;47: 106\u201312.","journal-title":"Obstet Gynecol"},{"key":"BF01830241_CR20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0010-7824(89)90092-9","volume":"40","author":"SA Brody","year":"1989","unstructured":"Brody SA, Turkes A, Goldzieher MD. Pharmacokinetics of three bioequivalent norethindrone\/mestranol and three norethindrone\/ethinyl estradiol-35 \u03bcg OC formulations: Are \u2018low-dose\u2019 pills really lower?Contraception 1989;40: 269\u201384.","journal-title":"Contraception"},{"key":"BF01830241_CR21","volume-title":"Managing Contraceptive Pill Patients","author":"RP Dickey","year":"1984","unstructured":"Dickey RP.Managing Contraceptive Pill Patients. 3rd ed. Durant, OK, USA: Creative Informatics, 1984.","edition":"3rd ed"},{"key":"BF01830241_CR22","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/ijc.2910490612","volume":"49","author":"KA Rosenblatt","year":"1991","unstructured":"Rosenblatt KA, Thomas DB, and The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma.Int J Cancer 1991;49: 870\u20134.","journal-title":"Int J Cancer"},{"key":"BF01830241_CR23","volume-title":"EGRET Software Package","author":"Statistics and Epidemiology Research Corporation","year":"1990","unstructured":"Statistics and Epidemiology Research Corporation.EGRET Software Package. Seattle, WA, USA: SERC, 1990."},{"unstructured":"Schlesselman JJ.Case-control Studies. Design, Conduct, Analysis. New York, NY, USA: Monographs in Epidemiology and Biostatistics, 1982.","key":"BF01830241_CR24"},{"key":"BF01830241_CR25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/0002-9378(76)90804-8","volume":"125","author":"RA Edgren","year":"1976","unstructured":"Edgren RA, Sturtevant FM. Potencies of oral contraceptives.Am J Obstet Gynecol 1976;125: 1029\u201338.","journal-title":"Am J Obstet Gynecol"},{"key":"BF01830241_CR26","volume-title":"Drug Evaluations","author":"American Medical Association","year":"1991","unstructured":"American Medical Association.Drug Evaluations, 6th ed. Chicago, IL, USA: American Medical Association, 1991.","edition":"6th ed."},{"key":"BF01830241_CR27","first-page":"371","volume":"38","author":"FM Sturtevant","year":"1984","unstructured":"Sturtevant FM. Breast cancer and oral contraceptives: Critique of the proposition that high potency progestogen products confer excess risk.Biomed Pharmacother 1984;38: 371\u20139.","journal-title":"Biomed Pharmacother"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01830241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01830241\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01830241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T19:05:07Z","timestamp":1557428707000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01830241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1994,5]]}},"alternative-id":["BF01830241"],"URL":"https:\/\/doi.org\/10.1007\/bf01830241","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"type":"print","value":"0957-5243"},{"type":"electronic","value":"1573-7225"}],"subject":[],"published":{"date-parts":[[1994,5]]}}}